TB treatment

TB treatment features

• 

  HIV and TB in Practice for nurses: Pregnancy and TB/HIV

  This article explains how to prevent and treat TB in pregnant women to protect both mother and child....

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice for nurses: Drug-resistant TB

  This article summarises the key recommendations on the diagnosis and treatment of drug-resistant TB for nurses, and highlights examples of best practice in their care....

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice for nurses: Starting ART for treatment and prevention in people with active TB and HIV

  This article provides information for nurses on starting HIV treatment for people with HIV and active TB....

  From:  HIV & AIDS treatment in practice

• 

  TB, HIV, mothers and children: time for action

  This year’s World TB Day edition of HATIP focusses on the needs of pregnant women and children with TB....

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice for nurses

  This is the first of a special monthly edition of HATiP for nurses and other health care workers involved in task-shifting in sub-Saharan Africa....

  From:  HIV & AIDS treatment in practice

• 

  Managing MDR-TB in the community: from presentation to cure or end-of-life care

  Part of a series, this edition examines the sequence of care of a person with drug-resistant TB. ...

  From:  HIV & AIDS treatment in practice

• 

  Decentralised, patient-centred models of delivering treatment and palliative care for people with M/XDR-TB

  Part of a series on improving care of multidrug-resistant tuberculosis, this edition examines delivery of treatment and palliative care, focusing on decentralised patient-centred TB care....

  From:  HIV & AIDS treatment in practice

• 

  HIV & TB in Practice: Improving clinical management of TB in people with HIV

  “If HIV and tuberculosis (TB) are both treatable diseases, why do some patients with HIV-associated TB require hospital admission and die?” asked Dr Graeme Meintjes,...

  From:  HIV & AIDS treatment in practice

• 

  WHO issues updated TB treatment guidelines

  Treatment regimens for tuberculosis should include an antibiotic of the rifamycin class for the full six months of therapy, according to new World Health Organization...

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice

  This articles looks at the issue of isoniazid resistance in isoniazid preventive therapy (IPT) and TB programmes. ...

  From:  HIV & AIDS treatment in practice

TB treatment in your own words

• 

  TB - my experiences

  This might sound odd, but I was really shocked when I became seriously ill because of HIV. I was even more shocked when it turned...

  From: In your own words

TB treatment news from aidsmap

• Steroids reduce mortality risk for people taking TB treatment

  Corticosteroid treatment is associated with a reduced risk of mortality for people taking tuberculosis (TB) therapy, results of a meta-analysis published in The Lancet Infectious Diseases show. Treatment with steroids was associated with a significant 17% reduction in mortality risk, ...

  24 March 2013 | Michael Carter

• Dosing of key TB drug rifampicin could go higher

  Rifampicin, a key drug in tuberculosis (TB) treatment, can be tolerated at much higher doses than used in current clinical practice – suggesting that much higher drug levels may lead to a more rapid treatment response, allowing the treatment ...

  07 March 2013 | Keith Alcorn

• Once-weekly continuation phase TB treatment equals standard of care

  A new two-drug combination of rifapentine and moxifloxacin can allow tuberculosis (TB) treatment to be taken once-weekly during the four-month continuation phase, Dr Amina Jindani of St George’s University Medical School, London, told the 20th Conference on Retroviruses and ...

  07 March 2013 | Keith Alcorn

• FDA Advisory Committee recommends accelerated approval of bedaquiline for drug-resistant TB

  Bedaquiline, the first agent in a new class of TB drug, has been recommended for accelerated approval by the Anti-Infective Drugs Advisory Committee of the United States Food and Drug Administration (FDA). The committee voted unanimously (18 to 0) ...

  03 December 2012 | Lesley Odendal

• Risk of recurrence of active TB is high for people with HIV

  People living with HIV who have a history of active tuberculosis (TB) have a significant risk of the recurrence of the disease, investigators report in the online edition of Clinical Infectious Diseases. The risk of developing active TB ...

  22 October 2012 | Michael Carter

• International study finds "worrying" levels of XDR-TB

  Results of an international study published in The Lancet show that 7% of people receiving second-line treatment for tuberculosis (TB) have extensively drug-resistant TB (XDR-TB). The investigators describe this finding as “worrying”. A total of 1278 people from eight countries were ...

  31 August 2012 | Michael Carter

• Raltegravir 800mg twice daily appears a good alternative to efavirenz for HIV-TB treatment

  Raltegravir seems to be a suitable alternative to efavirenz for HIV-TB co-infected patients while receiving TB treatment, according to 24-week results of the ANRS 12 180 REFLATE study presented at the Nineteenth International AIDS Conference (AIDS 2012) in Washington ...

  31 July 2012 | Lesley Odendal

• Novel TB combination regimen shows potent activity in randomised short-term clinical trial

  A new TB drug, PA-824, showed very potent early bactericidal activity in a randomised 14-day study in people with TB, when used in combination with the established antibiotic moxifloxacin, and pyrazinamide, an existing TB drug, according to a presentation by ...

  25 July 2012 | Theo Smart

• Co-administration of rifampicin and efavirenz does not reduce efavirenz concentrations or efficacy

  Standard dosing of efavirenz, that was not adjusted for patient weight, resulted in therapeutic efavirenz concentrations and excellent virological outcomes in patients coinfected with TB and HIV who were also taking a rifampicin-containing TB treatment, according to results from the ...

  24 July 2012 | Lesley Odendal

• Low CD4 cell count and older age associated with increased risk of TB after starting HIV therapy

  People with HIV reduce their overall risk of tuberculosis (TB) by starting antiretroviral therapy, an international team of investigators report in the online edition of Clinical Infectious Diseases. Despite this, the risk of the disease increased in the first ...

  11 April 2012 | Michael Carter

More news

TB treatment news selected from other sources

• The ongoing problem of tuberculosis in the UK

  The report of the All-Party Group on Global Tuberculosis gives grounds for optimism; although the task is huge it provides a coherent set of recommendations that can be taken on by a new public health body seeking to demonstrate its leadership and effectiveness. Successfully leading the strategy to eliminate tuberculosis in the UK should be an agreed metric to measure the performance of Public Health England.

  26 April 2013 | The Lancet (editorial)

• Researchers make a significant step forward in combating antibiotic resistance

  Antibiotic resistance is a global problem. The World Health Organisation (WHO) estimates that for tuberculosis alone multi-drug resistance accounts for more than 150,000 deaths each year. Now researchers are one step closer to understanding why antibiotics are ineffective against certain types of bacteria.

  25 April 2013 | Durham University News

• Rifapentine’s manufacturer helps to advance TB research while stalling access

  Sanofi-Aventis, manufacturer of the tuberculosis (TB) drug rifapentine (Priftin), can be credited for aiding research efforts to shorten and simplify treatment dosing for TB. However, the company’s pricing of the drug has hampered access to such regimens, even in resource-rich nations like the United States.

  12 April 2013 | Treatment Action Group

• Pill-watching practice may not improve tuberculosis treatment

  Tuberculosis patients who swallow their anti-tuberculosis pills under the watchful gaze of doctors fare just as well as patients trusted to self-medicate, according to a new analysis.

  05 April 2013 | Yahoo! News

• Pfizer's drug to treat tuberculosis in short supply

  The Food and Drug Administration has added Pfizer Inc's tuberculosis treatment rifampin to its list of drugs in short supply, the latest in a growing number of spottily available TB medications.

  25 March 2013 | Yahoo! News (blog)

• Southern Africa cracks down on TB in mines

  South Africa's gold mines are estimated to have the highest number of new tuberculosis (TB) cases in the world, making the disease a leading export to neighbouring countries. IRIN takes a look at the declaration meant to change this situation.

  25 March 2013 | IRIN

• African Health Ministers Commit to Ramped Up TB/HIV Treatment

  Health ministers from Swaziland and South Africa have agreed to radically change the diagnosis and treatment of the co-epidemic of TB/HIV in their countries.

  22 March 2013 | Voice of America

• An Activist’s Guide to Bedaquiline (Sirturo)

  Bedaquiline (also known by its trade name, Sirturo, or as TMC207) is the first new drug from a new drug class to treat TB to be approved by the United States Food and Drug Administration (FDA) in over 40 years. This guide highlights important safety and efficacy data reported thus far and offers advocacy recommendations for activists to take forward. .

  12 March 2013 | Treatment Action Group

• In India, Fighting TB with Fingerprints

  Health specialists in India are using fingerprint technology to make sure tuberculosis sufferers receive proper treatment for the deadly lung infection.

  28 February 2013 | Voice of America

• CDC report on U.S. TB drug shortage reflects local and global challenges

  According to an article in this week’s Morbidity and Mortality Weekly Report, the 26 health departments handling about 75 percent of the United States tuberculosis caseload have confronted multidrug-resistant tuberculosis, with 21 of those departments — more than 80 percent – facing obstacles to getting the medicine necessary to treat it.

  21 January 2013 | Science Speaks

More news